A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer
Interventions: DRUG: Pegilodecakin|DRUG: Paclitaxel or Docetaxel and Carboplatin or Cisplatin|DRUG: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|DRUG: gemcitabine/nab-paclitaxel|DRUG: Capecitabine|DRUG: Pazopanib|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: nivolumab|DRUG: Gemcitabine/carboplatin
Sponsor: Eli Lilly and Company
Collaborators: ARMO BioSciences